Scientists test new drug timing to outsmart tough cancers

This early-phase trial is testing a new way of giving two cancer drugs—olaparib and adavosertib—one after the other instead of together. The goal is to see if this sequence can shrink or stabilize advanced solid tumors that have spread and stopped responding to other treatments, while potentially causing fewer side effects. The study is enrolling adults with specific genetic mutations whose cancer has progressed after prior therapy, including a type of drug called a PARP inhibitor.